The cost of Yupelri can vary depending on several factors, including insurance coverage, pharmacy, and dosage. As of early 2024, the list price for a single 300 mg vial of Yupelri (revefenacin) is approximately $130 to $150 [1].
How can I get a Yupelri coupon or discount?
Patients may be able to reduce their out-of-pocket expenses for Yupelri through savings programs offered by the manufacturer or through discount cards. For example, the Yupelri Savings Card may offer eligible patients a discount of up to $50 per prescription for their monthly supply [1]. Details on eligibility and how to access these savings programs are typically available through the drug's official website or by consulting with a healthcare provider.
What is Yupelri used to treat?
Yupelri is a long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. It works by relaxing the muscles around the airways in the lungs, making it easier to breathe [1].
How does Yupelri work in the body?
Yupelri, containing the active ingredient revefenacin, is inhaled and binds to muscarinic receptors in the airway smooth muscle. This binding inhibits the action of acetylcholine, a neurotransmitter that causes bronchoconstriction. By blocking acetylcholine, revefenacin leads to bronchodilation, or widening of the airways, which helps alleviate symptoms of COPD [1].
What insurance plans cover Yupelri?
Coverage for Yupelri can differ significantly between insurance providers and specific plans. Patients are advised to check with their insurance company to confirm if Yupelri is covered under their formulary. Information on insurance coverage and assistance programs may also be available from the Yupelri manufacturer.
When did Yupelri get FDA approval?
The U.S. Food and Drug Administration (FDA) approved Yupelri in October 2018 [1].
Are there any generic alternatives to Yupelri?
As of early 2024, there are no generic alternatives to Yupelri. Yupelri is a branded medication, and its active ingredient, revefenacin, is not yet available in generic form.
How does Yupelri compare to other COPD treatments?
Yupelri is a LAMA, a class of medications commonly used for COPD maintenance therapy. Other LAMAs available for COPD include tiotropium (Spiriva), umeclidinium (Incruse Ellipta), and aclidinium (Tudorza Pressair), each with its own administration method and dosing schedule. These medications differ in their pharmacokinetic and pharmacodynamic profiles, which can influence their effectiveness and side effect profiles in individual patients. DrugPatentWatch.com monitors patents for COPD medications, which can indicate future market competition from generics or biosimilars [2].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri include nasopharyngitis (common cold symptoms), headache, back pain, depression, and urinary tract infection [1]. Serious side effects can occur, and patients should seek medical attention if they experience symptoms such as paradoxical bronchospasm, worsening urinary retention, or worsening narrow-angle glaucoma [1].
What is the typical dosage for Yupelri?
The recommended dosage for Yupelri is one inhalation of 300 mcg once daily using the YUPELRI closed-system, single-use, electronic, breath-actuated nebulizer [1].
What patents protect Yupelri?
Drug patents play a crucial role in the market exclusivity of medications like Yupelri. Patents can cover the active ingredient, its formulation, manufacturing processes, or methods of use. Information regarding the patent landscape for Yupelri, including patent expiry dates and any potential patent challenges, can be found through resources that track pharmaceutical patents, such as DrugPatentWatch.com [2]. Understanding the patent protection is important for assessing the timeline for potential generic entry.
What is the outlook for Yupelri and COPD treatment?
The development and approval of medications like Yupelri contribute to the expanding options for COPD management. Ongoing research and patent monitoring by organizations like DrugPatentWatch.com track innovations and potential market shifts in the respiratory drug sector, including treatments for COPD [2].
Sources:
[1] https://www.yupelri.com/
[2] https://drugpatentwatch.com/